• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: REVISION OPTICS, INC. RAINDROP NEAR VISION INLAY; CORNEAL INLAY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

REVISION OPTICS, INC. RAINDROP NEAR VISION INLAY; CORNEAL INLAY Back to Search Results
Model Number PP6-530-0027-US
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Corneal Clouding/Hazing (1878)
Event Date 08/30/2017
Event Type  Injury  
Manufacturer Narrative
The explanted inlay was returned to the manufacturer and subjected to visual microscopic inspection and dimensional analysis.The findings revealed that the inlay was received folded and damaged with large sections of the inlay torn off and the presence of several cuts and particles.The edge thickness was measured and found to be within specifications; however, the damaged condition of the inlay precluded measurement of the diameter.The damaged condition of the inlay is suspected as being caused by removal from the eye, excessive handling, and improper storage during transport.The device history record review of the manufacturing lot was performed and there were no discrepancies or unusual findings related to the reported issue.Corneal haze is listed in the device labeling as a known potential risk.(b)(4).
 
Event Description
The subject was enrolled in the (b)(6) clinical trial and underwent implantation of the investigational corneal inlay in the left eye on (b)(6) 2013.At the 48-month exam on (b)(6) 2017, the subject presented with grade 3 central corneal haze and durezol was prescribed.The subject was examined two weeks later and the slit lamp examination showed no improvement in haze; the inlay was explanted on (b)(6) 2017.The corneal haze did not result in a significant decrease in best corrected distance visual acuity.
 
Manufacturer Narrative
(b)(4).
 
Event Description
Patient follow-up was requested, and the following additional information was received.At last examination on (b)(6) 2017, the corneal haze reduced to grade 1, and the bcdva was 20/25 (44 letters).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RAINDROP NEAR VISION INLAY
Type of Device
CORNEAL INLAY
Manufacturer (Section D)
REVISION OPTICS, INC.
25651 atlantic ocean drive
suite a1
lake forest CA 92630 8835
Manufacturer (Section G)
REVISION OPTICS, INC.
25651 atlantic ocean drive
suite a1
lake forest CA 92630 8835
Manufacturer Contact
pushpita singh
25651 atlantic ocean drive
suite a1
lake forest, CA 92630-8835
9497072740
MDR Report Key6862835
MDR Text Key86076670
Report Number3005956347-2017-00101
Device Sequence Number1
Product Code LQE
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
G090149
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional,study,use
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 12/14/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Physician
Device Expiration Date05/31/2014
Device Model NumberPP6-530-0027-US
Device Lot Number002455
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer09/07/2017
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 08/15/2017
Initial Date FDA Received09/13/2017
Supplement Dates Manufacturer Received11/14/2017
Supplement Dates FDA Received12/14/2017
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured05/21/2013
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age53 YR
-
-